ABOUT US

Our goal is to help save lives everywhere — through noninvasive, easily accessed breath tests that merge clinical evidence and deep data analysis to prevent, detect, and personalize disease treatments.

Chris Marsh joined Revelar Health in May 2007 as chairman of the board and became CEO in January 2008, bringing a wealth of experience in strategic growth to the company.

Prior to Revelar, Chris was Chief Executive Officer at Unicru. He joined Unicru in April 2001 and under Chris' leadership, Unicru grew from 40 to 350 employees and was recognized in three of the last four years as one of the 500 fastest growing and most successful companies in the U.S. by Inc. Magazine and Deloitte & Touche.

In July 2006, Unicru was sold to Kronos, Inc. for $170 million, a four-times revenue multiple. Thereafter, Chris was appointed President of Kronos’s Talent Management Division, where within 10 months Kronos sold to a private equity fund for $1.8 billion.

Prior to Unicru, Chris was the EVP of E*Trade, the leading online financial brokerage firm and independent provider of ATMs. Prior to E*Trade, he was a CFO and COO for Card Capture Services (CCS) where he played an instrumental role in the sale of CCS to E*Trade. Prior to CCS, he was CEO of Superior Transportation Logistics, a company with over $75M in revenues, which he sold to The Greenbrier Companies. After the acquisition, he served as the EVP and Director of Greenbrier Logistic Companies until he left to join CCS.

Chris holds a B.S. in Business Administration from Oregon State University. He currently serves on the Board of Directors at ARM Insight, Inc., CloudMed Solutions, Henningsen Cold Storage, and Point B, Inc.

Linda McAllister, MD, PhD, joined Revelar in April 2018 as Chief Medical Officer. In this role, she is responsible for heading up the company’s clinical research efforts and partnering with executive and strategy teams to navigate future product opportunities and partnerships.

Before joining Revelar, Dr. McAllister was VP of Scientific Affairs and Innovation at Becton Dickinson. Previous to that role, she advised multiple early-stage device and diagnostic companies. Prior to consulting, Dr. McAllister held CMO positions at Xagenic, CellScape, PharmaJet, and Arbor Vita Corp. Prior to Arbor Vita Corp, Dr. McAllister held Director positions at Roche Diagnostics and Celera and was Scientific Liaison, Program Manager for Genotyping at Affymetrix.

Dr. McAllister received her B.S. in Biology and Chemistry from the California Institute of Technology (Caltech), where she conducted her research under the guidance of two Nobel Laureates. She received her Ph.D. in Neuroscience and M.D. from Stanford University Medical School. Dr. McAllister completed her residency in internal medicine at the UCSF Hospital and was a Bugher Cardiovascular Research Fellow at Stanford working on the first DNA microarrays. Linda also practiced medicine part time for ten years as a clinical faculty member at UCSF.

As Chief Financial Officer, John Dettra oversees all financial and fiscal management aspects of company operations. He is a seasoned financial executive with a strong background in strategic planning, mergers and acquisitions (private and publicly-traded), budgeting and analysis, financial management, and operational experience in high-growth companies.

Prior to joining Revelar, John served as Chief Financial Officer of Evanta Ventures, Inc., a private equity owned company that was the market leader in collaboration and leadership development platforms for top executives at enterprise level corporations. During his tenure at Evanta, the company realized significant revenue and profitability growth prior to being sold to CEB, Inc. for nearly $300 million, resulting in a return to shareholders of over four times in just over 3 years.

Prior to Evanta, John was Chief Financial Officer at Revelar. Prior to Revelar, he was VP of Finance and Administration at Unicru.

John is a Certified Management Accountant (CMA), and is a University of Oregon graduate.

Dan Fowkes joins Revelar Health with over 25 years of experience in technology sales. He has built and led numerous sales teams, with a track record of driving significant growth in start-up and early stage technology companies. Dan is a seasoned veteran in defining and executing on sales strategy and has also consulted to numerous companies, refining and implementing their sales strategies and processes.

Most recently, Dan built and ran the software sales organization and strategy for POS Portal, the leader in turn-key technology infrastructure for payments processing companies. Dan also designed and implemented the business models and sales strategies at start-ups Cloud Cruiser and Evolv, Inc.

Formerly, he was Sr. Vice President of Sales at Unicru, Inc., the leader in Work Force Optimization software for large enterprises. At Unicru, Dan hired and led the company’s sales and account management teams, with responsibility for all of the company’s revenue. He grew Unicru’s sales from an early stage to over $40 million in annual revenue and $160 million in contract value, leading to Unicru’s acquisition by Kronos, Inc. for $170 million in 2006. Prior to Unicru, Dan ran Worldwide Sales at Acuity, an Austin, TX based start-up, driving a 900% increase in sales in his first year, before it was acquired by Quintus at the end of 1999. Before Acuity, he was a National Sales Vice President for the Tele-communications business unit at PeopleSoft. Prior to PeopleSoft, Dan held several sales leadership positions over a seven-year span at CableData (USCS), the world’s leading customer care and billing software for cable television and other telecommunications industries — including three years as Vice President of North American Sales. He drove much of USCS’s revenue growth that led to their IPO in 1996. Dan holds a Bachelor’s Degree in Economics from Stanford University.

As Vice President of Operations, Maura Mahon oversees Revelar Health's operations and infrastructure. She has more than 20 years of experience in software implementation, program management and strategic alliance development. Prior to joining Revelar, Maura served as director of professional services with Kronos, where she was instrumental in acquisition strategy and enhanced resource quality and productivity.

Previously, she was a principal consultant with Cap Gemini Ernst & Young, and served as the director of eCommerce Practice with Emerald Solutions. Maura holds a bachelor's in mathematics and computer science from State University of New York, Albany, and is a certified Project Management Professional (PMP).

As Vice President of Global Support Operations, Nigel Havers leads creation and management of a world class organization that supports our customers’ use and experience with the Revelar platform. Nigel joins Revelar following 17 successful years in service, support and leadership in the Life Sciences industry with Affymetrix, recently acquired by Thermo Fisher Scientific. During his time at Affymetrix, Nigel led several key strategic initiatives focused on delivering improvement to customer experience and internal commercial operations using cloud-based technologies across the globe, including establishing new operations in the EMEA, Americas and Asia.

With a past career in corporate finance and IT gained in the Financial Service, Aviation and Automotive industries, Nigel brings a wealth of business experience to the leadership team at Revelar.

Chris Marsh joined Revelar Health in May 2007 as chairman of the board and became CEO in January 2008, bringing a wealth of experience in strategic growth to the company.

Prior to Revelar, Chris was Chief Executive Officer at Unicru. He joined Unicru in April 2001 and under Chris' leadership, Unicru grew from 40 to 350 employees and was recognized in three of the last four years as one of the 500 fastest growing and most successful companies in the U.S. by Inc. Magazine and Deloitte & Touche.

In July 2006, Unicru was sold to Kronos, Inc. for $170 million, a four-times revenue multiple. Thereafter, Chris was appointed President of Kronos’s Talent Management Division, where within 10 months Kronos sold to a private equity fund for $1.8 billion.

Prior to Unicru, Chris was the EVP of E*Trade, the leading online financial brokerage firm and independent provider of ATMs. Prior to E*Trade, he was a CFO and COO for Card Capture Services (CCS) where he played an instrumental role in the sale of CCS to E*Trade. Prior to CCS, he was CEO of Superior Transportation Logistics, a company with over $75M in revenues, which he sold to The Greenbrier Companies. After the acquisition, he served as the EVP and Director of Greenbrier Logistic Companies until he left to join CCS.

Chris holds a B.S. in Business Administration from Oregon State University. He currently serves on the Board of Directors at ARM Insight, Inc., CloudMed Solutions, Henningsen Cold Storage, and Point B, Inc.

Linda McAllister, MD, PhD, joined Revelar in April 2018 as Chief Medical Officer. In this role, she is responsible for heading up the company’s clinical research efforts and partnering with executive and strategy teams to navigate future product opportunities and partnerships.

Before joining Revelar, Dr. McAllister was VP of Scientific Affairs and Innovation at Becton Dickinson. Previous to that role, she advised multiple early-stage device and diagnostic companies. Prior to consulting, Dr. McAllister held CMO positions at Xagenic, CellScape, PharmaJet, and Arbor Vita Corp. Prior to Arbor Vita Corp, Dr. McAllister held Director positions at Roche Diagnostics and Celera and was Scientific Liaison, Program Manager for Genotyping at Affymetrix.

Dr. McAllister received her B.S. in Biology and Chemistry from the California Institute of Technology (Caltech), where she conducted her research under the guidance of two Nobel Laureates. She received her Ph.D. in Neuroscience and M.D. from Stanford University Medical School. Dr. McAllister completed her residency in internal medicine at the UCSF Hospital and was a Bugher Cardiovascular Research Fellow at Stanford working on the first DNA microarrays. Linda also practiced medicine part time for ten years as a clinical faculty member at UCSF.

As Chief Financial Officer, John Dettra oversees all financial and fiscal management aspects of company operations. He is a seasoned financial executive with a strong background in strategic planning, mergers and acquisitions (private and publicly-traded), budgeting and analysis, financial management, and operational experience in high-growth companies.

Prior to joining Revelar, John served as Chief Financial Officer of Evanta Ventures, Inc., a private equity owned company that was the market leader in collaboration and leadership development platforms for top executives at enterprise level corporations. During his tenure at Evanta, the company realized significant revenue and profitability growth prior to being sold to CEB, Inc. for nearly $300 million, resulting in a return to shareholders of over four times in just over 3 years.

Prior to Evanta, John was Chief Financial Officer at Revelar. Prior to Revelar, he was VP of Finance and Administration at Unicru.

John is a Certified Management Accountant (CMA), and is a University of Oregon graduate.

Dan Fowkes joins Revelar Health with over 25 years of experience in technology sales. He has built and led numerous sales teams, with a track record of driving significant growth in start-up and early stage technology companies. Dan is a seasoned veteran in defining and executing on sales strategy and has also consulted to numerous companies, refining and implementing their sales strategies and processes.

Most recently, Dan built and ran the software sales organization and strategy for POS Portal, the leader in turn-key technology infrastructure for payments processing companies. Dan also designed and implemented the business models and sales strategies at start-ups Cloud Cruiser and Evolv, Inc.

Formerly, he was Sr. Vice President of Sales at Unicru, Inc., the leader in Work Force Optimization software for large enterprises. At Unicru, Dan hired and led the company’s sales and account management teams, with responsibility for all of the company’s revenue. He grew Unicru’s sales from an early stage to over $40 million in annual revenue and $160 million in contract value, leading to Unicru’s acquisition by Kronos, Inc. for $170 million in 2006. Prior to Unicru, Dan ran Worldwide Sales at Acuity, an Austin, TX based start-up, driving a 900% increase in sales in his first year, before it was acquired by Quintus at the end of 1999. Before Acuity, he was a National Sales Vice President for the Tele-communications business unit at PeopleSoft. Prior to PeopleSoft, Dan held several sales leadership positions over a seven-year span at CableData (USCS), the world’s leading customer care and billing software for cable television and other telecommunications industries — including three years as Vice President of North American Sales. He drove much of USCS’s revenue growth that led to their IPO in 1996. Dan holds a Bachelor’s Degree in Economics from Stanford University.

As Vice President of Operations, Maura Mahon oversees Revelar Health's operations and infrastructure. She has more than 20 years of experience in software implementation, program management and strategic alliance development. Prior to joining Revelar, Maura served as director of professional services with Kronos, where she was instrumental in acquisition strategy and enhanced resource quality and productivity.

Previously, she was a principal consultant with Cap Gemini Ernst & Young, and served as the director of eCommerce Practice with Emerald Solutions. Maura holds a bachelor's in mathematics and computer science from State University of New York, Albany, and is a certified Project Management Professional (PMP).

As Vice President of Global Support Operations, Nigel Havers leads creation and management of a world class organization that supports our customers’ use and experience with the Revelar platform. Nigel joins Revelar following 17 successful years in service, support and leadership in the Life Sciences industry with Affymetrix, recently acquired by Thermo Fisher Scientific. During his time at Affymetrix, Nigel led several key strategic initiatives focused on delivering improvement to customer experience and internal commercial operations using cloud-based technologies across the globe, including establishing new operations in the EMEA, Americas and Asia.

With a past career in corporate finance and IT gained in the Financial Service, Aviation and Automotive industries, Nigel brings a wealth of business experience to the leadership team at Revelar.

Mark Goldston joined Revelar Health as Executive Chairman of the Board in September 2014. He is currently the Chairman and CEO of The Goldston Group in Los Angeles, California, which is a firm primarily focused on venture capital and emerging growth company investing and providing strategic advisory services to a range of companies and Private Equity firms. He is the major investor, co-founder and General Partner of Athletic Propulsion Labs, LLC, an athletic footwear and apparel company based in Los Angeles.

Previously from 2001-2013 Mark was the Chairman, President and CEO of United Online, Inc (Nasdaq: UNTD), an internet conglomerate consisting of NetZero, Juno, FTD Group, Interflora UK, Classmates, MyPoints, and StayFriends. United Online was created in September 2001 with the merger of NetZero and Juno Online. Previously, Mark had been the Chairman, President and CEO of NetZero from 1999-2001. He was one of the earliest employees of NetZero, the first Chairman and CEO of the company as a startup and took the company public in September 1999. In November 2013, United Online executed a tax-free spinoff of its FTD Group subsidiary creating two independent public companies; United Online and FTD Companies. Just prior to the separation of the two companies, United Online had generated $1.8 billion of cumulative adjusted OIBDA since 2001, had in excess of 100 million registered users and was one of the largest social networking, internet access and e-commerce companies in the USA.

In the 15 years prior to NetZero/United Online, Mark was the Chairman and CEO of The Goldston Group, President and CEO of Einstein/Noah Bagel Corp., President of L.A. Gear, Principal of Odyssey Partners, Chief Marketing Officer of Reebok, President of Faberge USA, Inc. and V.P. of Worldwide Fragrance and Skincare Marketing for Revlon.

Mark is an accomplished inventor with 63 U.S. and Foreign patents covering such inventions as lighted shoes, inflatable pump shoes, spring-loaded performance technology, energy return systems, internet search, targeted internet advertising, etc. He is also the author of The Turnaround Prescription, Repositioning Troubled Companies.

Mark holds an undergraduate B.S.B.A. Degree from The Ohio State University with a dual major in Marketing and Finance and an MBA (MM) Degree from the Northwestern University Kellogg School of Management with a dual major in Marketing and Finance.

Chris Marsh joined Revelar Health in May 2007 as chairman of the board and became CEO in January 2008, bringing a wealth of experience in strategic growth to the company.

Prior to Revelar, Chris was Chief Executive Officer at Unicru. He joined Unicru in April 2001 and under Chris' leadership, Unicru grew from 40 to 350 employees and was recognized in three of the last four years as one of the 500 fastest growing and most successful companies in the U.S. by Inc. Magazine and Deloitte & Touche.

In July 2006, Unicru was sold to Kronos, Inc. for $170 million, a four-times revenue multiple. Thereafter, Chris was appointed President of Kronos’s Talent Management Division, where within 10 months Kronos sold to a private equity fund for $1.8 billion.

Prior to Unicru, Chris was the EVP of E*Trade, the leading online financial brokerage firm and independent provider of ATMs. Prior to E*Trade, he was a CFO and COO for Card Capture Services (CCS) where he played an instrumental role in the sale of CCS to E*Trade. Prior to CCS, he was CEO of Superior Transportation Logistics, a company with over $75M in revenues, which he sold to The Greenbrier Companies. After the acquisition, he served as the EVP and Director of Greenbrier Logistic Companies until he left to join CCS.

Chris holds a B.S. in Business Administration from Oregon State University. He currently serves on the Board of Directors at ARM Insight, Inc., CloudMed Solutions, Henningsen Cold Storage, and Point B, Inc.p

Dr. Skye Lininger is Co-Founder, Chief Executive Officer and Chairman of Aisle7, a business that designs customized wellness-driven shopper marketing programs.

Dr. Lininger has more than 20 years of experience in the computer and software industry and has served as Vice President of Sales and Marketing for a dietary supplement company. Additionally, Dr. Lininger practiced chiropractic medicine for ten years.

Mr. Toor is a Partner and the Chief Investment Officer of Luzich Partners, a multi-strategy investment fund with a focus on both public and private equity investments. Previously, Mr. Toor was Founder and Chief Investment Officer of BlackRoot Capital, an investment fund focused on small-cap public equities and special situations.

Prior to BlackRoot Capital, Mr. Toor served as Managing Director of Jefferies & Company Inc., from April 2001 to December 2006. He also served as Head of Media Investment Banking at Jefferies, where he began working in 1994, and served as a member of the Investment Banking Management Group.

Mr. Toor began his career in investment banking with Kidder Peabody & Co. in New York in 1990. He holds a Bachelor of Arts degree in Economics from Ohio Wesleyan University and a Masters in Business Administration from Harvard Business School.

Beau was the fourth generation member of the Wrigley family to lead the Wm. Wrigley Jr. Company, a global leader in confections founded in 1891. He began his career with the company in 1985 and, after serving in multiple roles, became the Chairman, President and CEO in 1999. During his leadership, the Wrigley Company tripled in size and expanded its reach to consumers in 180 countries. In 2008, Wrigley was sold to privately held and family-owned Mars, Incorporated.

Currently, Beau is Chairman and CEO of Wrigley Management Inc., a family office, and WWJr. Enterprises Inc., an investment company that invests in a range of venture capital and private equity interests. He is a Senior Advisor to BDT Capital Partners, a merchant bank that provides long-term capital and advisory services to entrepreneurs and family-owned companies. Beau also is Co-Founder and Chairman of higi, a wellness and incentive reward platform that empowers individuals to measure and manage their personal health and well-being through 8,000 higi Stations nationwide, a higi website, a mobile app, wellness competitions, and incentives. Beau also has significant experience serving on public company boards, such as Hyatt Hotels Corporation for which he is a director, as well as the boards of various private and not-for-profit organizations.

Beau is an active philanthropist, currently serving as a Trustee of Conservation International and Co-Chair of their Ocean Health Council. Inspired by his passion for ocean conservation and diving, he was the originator and provided the founding grant for the Ocean Health Index (OHI), the first comprehensive global measurement of ocean health that scientifically compares and combines all dimensions of ocean health — biological, physical, economic and social.

Beau is a 1985 graduate of Duke University with a B.A. in Economics and attended the Wharton School of Business Advanced Management Program in 1994. Additionally, he was in the 1997 inaugural class of the Aspen Institute’s Henry Crown Fellowship Program.

Dr. Murray Lappe grew up in Skokie, Illinois as a self-proclaimed serial entrepreneur since the age of 6. Dr. Lappe is credited with creating the world’s first computer-based kiosk, which began his interest in computers, software, and informatics. Murray attended college at University of Illinois and then continued on to medical school at Northwestern University in Chicago. After a residency at Cedars-Sinai Medical Center in Los Angeles, he began his career as a physician with an interest in human genetics and medical informatics. He spent a year in a research program in genetics at Children’s Hospital LA.

After 8 years of medical practice, Dr. Lappe hung up his stethoscope when he founded a software company and data processing company in the field of substance abuse in the workplace. As his service company grew, he made several acquisitions of businesses in his field. When he owned the largest drug testing services company in the industry, with over 300 employees, he patented a new method for testing samples for drugs at the point of care. After his idea to transform the industry to the point of care, he bet it all, and founded eScreen. Today, Murray holds 17 patents and created the first workplace drug testing program in the country with an internet enabled instrument. His system is the most widely used in corporate America, by the US Army, Department of Defense, FedEx, WalMart, USPS, Sears, Kmart, and most of the Fortune 500.

Working from his garage, he built the world’s largest drug testing company, eScreen, with over 500 employees and transformed an entire industry. In 2012, eScreen was sold to Alere, Inc. for nearly $300 million, and served as Alere’s Chief Innovation Officer until December, 2014. Today, Dr. Lappe specializes in medical device development, and investments in healthcare technologies. He is Chairman/CEO of SteriMed, Four Futures Investments, Medical Director, Emerge Diagnostics, and advisor to a healthcare private equity group.

Jillian Manus is an experienced banking and media executive, a technology investor, and entrepreneur. She is the Managing Partner of Structure Capital, a Silicon Valley-based venture capital firm that invests in early-stage technology companies. In her role with Structure Capital, Jillian provides strategic support to founding teams focused on creating value in underutilized assets and excess capacity. She serves on the boards of several of her portfolio companies, including Hyp3r, Iggbo, and Liquiglide. 

Prior to Structure Capital, Jillian was Founder of Broad Strategy, Manus Media, and Global Goal Sports Management. 

Earlier in her career, Jillian worked in banking and media, serving as M&A co-director of TMT for Credit Suisse Zurich, and later as Director of Development for Universal and Warner Bros. Studios. She became interested in technology investing after serving as Associate Publisher of Upside, a San Francisco-based business and technology magazine for venture capitalists. 

Jillian chaired the Board of The Women's Conference, where she joined California’s then First Lady Maria Shriver, to create the world’s largest conference addressing issues important to women. Jillian is an active philanthropist and sits on the boards of Stanford University Digital Health, Stanford University School of Medicine Board of Fellows, DukeEngage, NYU Tisch School of the Arts, Advisory Board of the Center for Entrepreneurship and Innovation at the Fuqua School of Business at Duke University, and Communities in Schools. 

As a frequent global public speaker, Jillian provides business and political commentary at events and in the media, primarily for Bloomberg, Fox News, and CNBC’s Squawk Box. Currently she serves as a co-host on the podcast The Pitch, which has been called “a better, more realistic version of Shark Tank.” 

Jillian attended The University of Oxford and NYU, where she served on the Board of Trustees. She was named one of the Most Influential Women in Bay Area Business 2016 by the San Francisco Business Times. 

Robert A. Figlin, MD, FACP, is the Steven Spielberg Family Chair in Hematology Oncology, Professor of Medicine and Biomedical Sciences, Director of the Division of Hematology/Oncology, Deputy Director of the Samuel Oschin Comprehensive Cancer Institute and Deputy Director, Integrated Oncology Service Line at Cedars-Sinai Medical Center in Los Angeles, California. Dr. Figlin received his medical degree from the Medical College of Pennsylvania. He completed his residency and chief residency in internal medicine at Cedars-Sinai Medical Center and a fellowship in hematology/oncology at the David Geffen School of Medicine at UCLA. He is an Emeritus Professor of Medicine and Urology at the David Geffen School of Medicine at UCLA.

Prior to joining Cedars-Sinai, Dr. Figlin was the Arthur and Rosalie Kaplan Endowed Chair of the Department of Medical Oncology and Therapeutics Research, and the Associate Director for Clinical Research at the City of Hope Comprehensive Cancer Center. Prior to that, Dr. Figlin served as the Henry Alvin and Carrie L. Meinhardt Endowed Chair in Urologic Oncology and Professor of Medicine and Urology in the Divisions of Hematology/Oncology and Urologic Oncology at the David Geffen School of Medicine at UCLA. Dr. Figlin joined the UCLA faculty as Assistant Professor of Medicine in the Division of Hematology/Oncology and was appointed Co-Director of the Jonsson Comprehensive Cancer Center’s Oncology Program. He also held the post of Medical Director of the Thoracic and Genitourinary Oncology Program in the Departments of Medicine, Surgery and Urology, and served as Program Director of Solid Tumor Developmental Therapeutics within the Cancer Center. Dr. Figlin serves as Editor for Kidney Cancer Journal, and his studies have appeared in Clinical Cancer Research, Journal of Clinical Oncology, New England Journal of Medicine, Lancet, JNCI, Lancet Oncology, and Journal of Urology, among others. He has authored over 350 peer reviewed articles, more than 70 book chapters, and has published as editor multiple books in kidney cancer. He is the Editor of the recently released book by Springer Science entitled, Renal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Targets.

A nationally recognized leader in genitourinary and thoracic oncology, Dr. Figlin’s research focuses on renal cell carcinoma and thoracic malignancies. He established and directs the Kidney Cancer Program at Cedars-Sinai Medical Center, which aims to understand the biology of kidney cancer and translate that knowledge into novel treatment approaches. His leadership in developing novel anticancer drugs that avoid the toxicity associated with standard treatments furthers Cedars-Sinai’s tradition of compassionate patient care.

Mark Goldston joined Revelar Health as Executive Chairman of the Board in September 2014. He is currently the Chairman and CEO of The Goldston Group in Los Angeles, California, which is a firm primarily focused on venture capital and emerging growth company investing and providing strategic advisory services to a range of companies and Private Equity firms. He is the major investor, co-founder and General Partner of Athletic Propulsion Labs, LLC, an athletic footwear and apparel company based in Los Angeles.

Previously from 2001-2013 Mark was the Chairman, President and CEO of United Online, Inc (Nasdaq: UNTD), an internet conglomerate consisting of NetZero, Juno, FTD Group, Interflora UK, Classmates, MyPoints, and StayFriends. United Online was created in September 2001 with the merger of NetZero and Juno Online. Previously, Mark had been the Chairman, President and CEO of NetZero from 1999-2001. He was one of the earliest employees of NetZero, the first Chairman and CEO of the company as a startup and took the company public in September 1999. In November 2013, United Online executed a tax-free spinoff of its FTD Group subsidiary creating two independent public companies; United Online and FTD Companies. Just prior to the separation of the two companies, United Online had generated $1.8 billion of cumulative adjusted OIBDA since 2001, had in excess of 100 million registered users and was one of the largest social networking, internet access and e-commerce companies in the USA.

In the 15 years prior to NetZero/United Online, Mark was the Chairman and CEO of The Goldston Group, President and CEO of Einstein/Noah Bagel Corp., President of L.A. Gear, Principal of Odyssey Partners, Chief Marketing Officer of Reebok, President of Faberge USA, Inc. and V.P. of Worldwide Fragrance and Skincare Marketing for Revlon.

Mark is an accomplished inventor with 63 U.S. and Foreign patents covering such inventions as lighted shoes, inflatable pump shoes, spring-loaded performance technology, energy return systems, internet search, targeted internet advertising, etc. He is also the author of The Turnaround Prescription, Repositioning Troubled Companies.

Mark holds an undergraduate B.S.B.A. Degree from The Ohio State University with a dual major in Marketing and Finance and an MBA (MM) Degree from the Northwestern University Kellogg School of Management with a dual major in Marketing and Finance.

Chris Marsh joined Revelar Health in May 2007 as chairman of the board and became CEO in January 2008, bringing a wealth of experience in strategic growth to the company.

Prior to Revelar, Chris was Chief Executive Officer at Unicru. He joined Unicru in April 2001 and under Chris' leadership, Unicru grew from 40 to 350 employees and was recognized in three of the last four years as one of the 500 fastest growing and most successful companies in the U.S. by Inc. Magazine and Deloitte & Touche.

In July 2006, Unicru was sold to Kronos, Inc. for $170 million, a four-times revenue multiple. Thereafter, Chris was appointed President of Kronos’s Talent Management Division, where within 10 months Kronos sold to a private equity fund for $1.8 billion.

Prior to Unicru, Chris was the EVP of E*Trade, the leading online financial brokerage firm and independent provider of ATMs. Prior to E*Trade, he was a CFO and COO for Card Capture Services (CCS) where he played an instrumental role in the sale of CCS to E*Trade. Prior to CCS, he was CEO of Superior Transportation Logistics, a company with over $75M in revenues, which he sold to The Greenbrier Companies. After the acquisition, he served as the EVP and Director of Greenbrier Logistic Companies until he left to join CCS.

Chris holds a B.S. in Business Administration from Oregon State University. He currently serves on the Board of Directors at ARM Insight, Inc., CloudMed Solutions, Henningsen Cold Storage, and Point B, Inc.p

Dr. Skye Lininger is Co-Founder, Chief Executive Officer and Chairman of Aisle7, a business that designs customized wellness-driven shopper marketing programs.

Dr. Lininger has more than 20 years of experience in the computer and software industry and has served as Vice President of Sales and Marketing for a dietary supplement company. Additionally, Dr. Lininger practiced chiropractic medicine for ten years.

Mr. Toor is a Partner and the Chief Investment Officer of Luzich Partners, a multi-strategy investment fund with a focus on both public and private equity investments. Previously, Mr. Toor was Founder and Chief Investment Officer of BlackRoot Capital, an investment fund focused on small-cap public equities and special situations.

Prior to BlackRoot Capital, Mr. Toor served as Managing Director of Jefferies & Company Inc., from April 2001 to December 2006. He also served as Head of Media Investment Banking at Jefferies, where he began working in 1994, and served as a member of the Investment Banking Management Group.

Mr. Toor began his career in investment banking with Kidder Peabody & Co. in New York in 1990. He holds a Bachelor of Arts degree in Economics from Ohio Wesleyan University and a Masters in Business Administration from Harvard Business School.

Beau was the fourth generation member of the Wrigley family to lead the Wm. Wrigley Jr. Company, a global leader in confections founded in 1891. He began his career with the company in 1985 and, after serving in multiple roles, became the Chairman, President and CEO in 1999. During his leadership, the Wrigley Company tripled in size and expanded its reach to consumers in 180 countries. In 2008, Wrigley was sold to privately held and family-owned Mars, Incorporated.

Currently, Beau is Chairman and CEO of Wrigley Management Inc., a family office, and WWJr. Enterprises Inc., an investment company that invests in a range of venture capital and private equity interests. He is a Senior Advisor to BDT Capital Partners, a merchant bank that provides long-term capital and advisory services to entrepreneurs and family-owned companies. Beau also is Co-Founder and Chairman of higi, a wellness and incentive reward platform that empowers individuals to measure and manage their personal health and well-being through 8,000 higi Stations nationwide, a higi website, a mobile app, wellness competitions, and incentives. Beau also has significant experience serving on public company boards, such as Hyatt Hotels Corporation for which he is a director, as well as the boards of various private and not-for-profit organizations.

Beau is an active philanthropist, currently serving as a Trustee of Conservation International and Co-Chair of their Ocean Health Council. Inspired by his passion for ocean conservation and diving, he was the originator and provided the founding grant for the Ocean Health Index (OHI), the first comprehensive global measurement of ocean health that scientifically compares and combines all dimensions of ocean health — biological, physical, economic and social.

Beau is a 1985 graduate of Duke University with a B.A. in Economics and attended the Wharton School of Business Advanced Management Program in 1994. Additionally, he was in the 1997 inaugural class of the Aspen Institute’s Henry Crown Fellowship Program.

Dr. Murray Lappe grew up in Skokie, Illinois as a self-proclaimed serial entrepreneur since the age of 6. Dr. Lappe is credited with creating the world’s first computer-based kiosk, which began his interest in computers, software, and informatics. Murray attended college at University of Illinois and then continued on to medical school at Northwestern University in Chicago. After a residency at Cedars-Sinai Medical Center in Los Angeles, he began his career as a physician with an interest in human genetics and medical informatics. He spent a year in a research program in genetics at Children’s Hospital LA.

After 8 years of medical practice, Dr. Lappe hung up his stethoscope when he founded a software company and data processing company in the field of substance abuse in the workplace. As his service company grew, he made several acquisitions of businesses in his field. When he owned the largest drug testing services company in the industry, with over 300 employees, he patented a new method for testing samples for drugs at the point of care. After his idea to transform the industry to the point of care, he bet it all, and founded eScreen. Today, Murray holds 17 patents and created the first workplace drug testing program in the country with an internet enabled instrument. His system is the most widely used in corporate America, by the US Army, Department of Defense, FedEx, WalMart, USPS, Sears, Kmart, and most of the Fortune 500.

Working from his garage, he built the world’s largest drug testing company, eScreen, with over 500 employees and transformed an entire industry. In 2012, eScreen was sold to Alere, Inc. for nearly $300 million, and served as Alere’s Chief Innovation Officer until December, 2014. Today, Dr. Lappe specializes in medical device development, and investments in healthcare technologies. He is Chairman/CEO of SteriMed, Four Futures Investments, Medical Director, Emerge Diagnostics, and advisor to a healthcare private equity group.

Jillian Manus is an experienced banking and media executive, a technology investor, and entrepreneur. She is the Managing Partner of Structure Capital, a Silicon Valley-based venture capital firm that invests in early-stage technology companies. In her role with Structure Capital, Jillian provides strategic support to founding teams focused on creating value in underutilized assets and excess capacity. She serves on the boards of several of her portfolio companies, including Hyp3r, Iggbo, and Liquiglide. 

Prior to Structure Capital, Jillian was Founder of Broad Strategy, Manus Media, and Global Goal Sports Management. 

Earlier in her career, Jillian worked in banking and media, serving as M&A co-director of TMT for Credit Suisse Zurich, and later as Director of Development for Universal and Warner Bros. Studios. She became interested in technology investing after serving as Associate Publisher of Upside, a San Francisco-based business and technology magazine for venture capitalists. 

Jillian chaired the Board of The Women's Conference, where she joined California’s then First Lady Maria Shriver, to create the world’s largest conference addressing issues important to women. Jillian is an active philanthropist and sits on the boards of Stanford University Digital Health, Stanford University School of Medicine Board of Fellows, DukeEngage, NYU Tisch School of the Arts, Advisory Board of the Center for Entrepreneurship and Innovation at the Fuqua School of Business at Duke University, and Communities in Schools. 

As a frequent global public speaker, Jillian provides business and political commentary at events and in the media, primarily for Bloomberg, Fox News, and CNBC’s Squawk Box. Currently she serves as a co-host on the podcast The Pitch, which has been called “a better, more realistic version of Shark Tank.” 

Jillian attended The University of Oxford and NYU, where she served on the Board of Trustees. She was named one of the Most Influential Women in Bay Area Business 2016 by the San Francisco Business Times. 

Robert A. Figlin, MD, FACP, is the Steven Spielberg Family Chair in Hematology Oncology, Professor of Medicine and Biomedical Sciences, Director of the Division of Hematology/Oncology, Deputy Director of the Samuel Oschin Comprehensive Cancer Institute and Deputy Director, Integrated Oncology Service Line at Cedars-Sinai Medical Center in Los Angeles, California. Dr. Figlin received his medical degree from the Medical College of Pennsylvania. He completed his residency and chief residency in internal medicine at Cedars-Sinai Medical Center and a fellowship in hematology/oncology at the David Geffen School of Medicine at UCLA. He is an Emeritus Professor of Medicine and Urology at the David Geffen School of Medicine at UCLA.

Prior to joining Cedars-Sinai, Dr. Figlin was the Arthur and Rosalie Kaplan Endowed Chair of the Department of Medical Oncology and Therapeutics Research, and the Associate Director for Clinical Research at the City of Hope Comprehensive Cancer Center. Prior to that, Dr. Figlin served as the Henry Alvin and Carrie L. Meinhardt Endowed Chair in Urologic Oncology and Professor of Medicine and Urology in the Divisions of Hematology/Oncology and Urologic Oncology at the David Geffen School of Medicine at UCLA. Dr. Figlin joined the UCLA faculty as Assistant Professor of Medicine in the Division of Hematology/Oncology and was appointed Co-Director of the Jonsson Comprehensive Cancer Center’s Oncology Program. He also held the post of Medical Director of the Thoracic and Genitourinary Oncology Program in the Departments of Medicine, Surgery and Urology, and served as Program Director of Solid Tumor Developmental Therapeutics within the Cancer Center. Dr. Figlin serves as Editor for Kidney Cancer Journal, and his studies have appeared in Clinical Cancer Research, Journal of Clinical Oncology, New England Journal of Medicine, Lancet, JNCI, Lancet Oncology, and Journal of Urology, among others. He has authored over 350 peer reviewed articles, more than 70 book chapters, and has published as editor multiple books in kidney cancer. He is the Editor of the recently released book by Springer Science entitled, Renal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Targets.

A nationally recognized leader in genitourinary and thoracic oncology, Dr. Figlin’s research focuses on renal cell carcinoma and thoracic malignancies. He established and directs the Kidney Cancer Program at Cedars-Sinai Medical Center, which aims to understand the biology of kidney cancer and translate that knowledge into novel treatment approaches. His leadership in developing novel anticancer drugs that avoid the toxicity associated with standard treatments furthers Cedars-Sinai’s tradition of compassionate patient care.

Dr. Terence Risby received his PhD in Chemistry from Imperial College of Science Technology and Medicine London in 1970. After post-doctoral fellowships at the University of Madrid and the University of North Carolina, he was appointed assistant professor of Chemistry at the Pennsylvania State University. In 1979, he was appointed associate professor of Environmental Health Sciences at Johns Hopkins University and was promoted to professor in 1987. In 2004, after an academic career of more than 30 years, he retired and was appointed professor emeritus. Dr. Risby’s interests in breath biomarkers of tissue injury, disease progression, and therapy began more than twenty-five years ago when he designed and successfully completed a pilot study to modify existing breath analysis and sampling techniques for use intra-operatively. He is a founding member for the International Association for Breath Research (IABR) and the Journal of Breath Research (JBR). Terence is an associate editor of the journal Biomarkers. Dr. Risby’s group has published more than 100 articles in peer-reviewed journals as well as monographs, books and book chapters. The current focus of Dr. Risby’s research group is the use of breath biomarkers in clinical molecular epidemiological studies.

Dr. James D. Ingle is a Professor Emeritus of Chemistry at Oregon State University. He has worked over 40 years in analytical and environmental chemistry with expertise in spectrochemical analysis based with absorption, fluorescence, and chemiluminescence detection and atomic spectrometery, portable and miniature analyzers and sensors, on-line preconcentration techniques, microfluidics, and miniature flow analyzers. He is known worldwide for his graduate textbook and reference titled "Spectrochemical Analysis" and near 100 publications.

As CEO, Mr. King set Icon Time Systems on a path of heavy growth. While CEO, Icon Time Systems was ranked by the Portland Business Journal as one of Oregon's fastest growing businesses five years in a row, ranking 23rd in 2003, 25th in 2004, 75th in 2005, and most recently, 33rd in 2006 and 2007. In 2008, Icon Time Systems was listed as Oregon's 9th fastest growing technology company by the Portland Business Journal, and has been ranked on the top half of Inc. Magazines fast 5000.

Along the way, Mr. King has served on the Board of Directors of the Business Enterprise Center — an incubator for startup technology companies in Corvallis, Oregon. Within his field he has served as Education Chairman and Board member of the National Time And Equipment Association, the primary trade group for his industry. While serving with the NTEA, Mr. King was the first vendor member to achieve voting rights, and be asked to remain on the board for two consecutive terms. Mr. King also participates, through Focus Point Consulting, in a CEO group that advises each other on business development and strategic planning.

While at Icon Time Systems he guided expansion into mass-market retail channels, lead the movement of development and production to off-shore resources and ultimately guided the sale of Icon Time Systems to Paychex, Inc. (NASDAQ: PAYX).

Mr. King's work has resulted in two patents issued by the US Patents and Trademark office, with several others pending approval. He also actively serves on the Board of Advisors to Plant Protectors, a startup company manufacturing green products for the garden supply industry and NASEA, an alternative wave energy startup. In his role of guiding development teams, Mr. King has successfully lead the development of more than 20 products from design to distribution.

Dr. Terence Risby received his PhD in Chemistry from Imperial College of Science Technology and Medicine London in 1970. After post-doctoral fellowships at the University of Madrid and the University of North Carolina, he was appointed assistant professor of Chemistry at the Pennsylvania State University. In 1979, he was appointed associate professor of Environmental Health Sciences at Johns Hopkins University and was promoted to professor in 1987. In 2004, after an academic career of more than 30 years, he retired and was appointed professor emeritus. Dr. Risby’s interests in breath biomarkers of tissue injury, disease progression, and therapy began more than twenty-five years ago when he designed and successfully completed a pilot study to modify existing breath analysis and sampling techniques for use intra-operatively. He is a founding member for the International Association for Breath Research (IABR) and the Journal of Breath Research (JBR). Terence is an associate editor of the journal Biomarkers. Dr. Risby’s group has published more than 100 articles in peer-reviewed journals as well as monographs, books and book chapters. The current focus of Dr. Risby’s research group is the use of breath biomarkers in clinical molecular epidemiological studies.

Dr. James D. Ingle is a Professor Emeritus of Chemistry at Oregon State University. He has worked over 40 years in analytical and environmental chemistry with expertise in spectrochemical analysis based with absorption, fluorescence, and chemiluminescence detection and atomic spectrometery, portable and miniature analyzers and sensors, on-line preconcentration techniques, microfluidics, and miniature flow analyzers. He is known worldwide for his graduate textbook and reference titled "Spectrochemical Analysis" and near 100 publications.

As CEO, Mr. King set Icon Time Systems on a path of heavy growth. While CEO, Icon Time Systems was ranked by the Portland Business Journal as one of Oregon's fastest growing businesses five years in a row, ranking 23rd in 2003, 25th in 2004, 75th in 2005, and most recently, 33rd in 2006 and 2007. In 2008, Icon Time Systems was listed as Oregon's 9th fastest growing technology company by the Portland Business Journal, and has been ranked on the top half of Inc. Magazines fast 5000.

Along the way, Mr. King has served on the Board of Directors of the Business Enterprise Center — an incubator for startup technology companies in Corvallis, Oregon. Within his field he has served as Education Chairman and Board member of the National Time And Equipment Association, the primary trade group for his industry. While serving with the NTEA, Mr. King was the first vendor member to achieve voting rights, and be asked to remain on the board for two consecutive terms. Mr. King also participates, through Focus Point Consulting, in a CEO group that advises each other on business development and strategic planning.

While at Icon Time Systems he guided expansion into mass-market retail channels, lead the movement of development and production to off-shore resources and ultimately guided the sale of Icon Time Systems to Paychex, Inc. (NASDAQ: PAYX).

Mr. King's work has resulted in two patents issued by the US Patents and Trademark office, with several others pending approval. He also actively serves on the Board of Advisors to Plant Protectors, a startup company manufacturing green products for the garden supply industry and NASEA, an alternative wave energy startup. In his role of guiding development teams, Mr. King has successfully lead the development of more than 20 products from design to distribution.